Passage BIO, Inc.
Developing genetic medicines for severe CNS and neurodegenerative disorders.
PASG | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- ONE COMMERCE SQUARE, 19103 PHILADELPHIA
- Website:
- https://www.passagebio.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on developing transformative therapies for patients with neurodegenerative and other severe central nervous system (CNS) disorders. The company's mission is to deliver genetic medicines designed to permanently redefine the course of these conditions. Passage Bio advances a pipeline of treatments for rare, monogenic CNS diseases. Its lead clinical program includes the upliFT-D study, a Phase 1/2 trial evaluating the safety and efficacy of PBFT02, a gene therapy for patients with frontotemporal dementia (FTD) with progranulin gene mutations.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Passage BIO, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Passage BIO, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Passage BIO, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
